Tenboron Oy (Finland) was awarded funding from Horizon Europe’s 2025 Health Call, ‘Boosting the translation of biotech research into innovative health therapies’. With an overall budget of €7.6 million, the…
Cardiovascular disease remains one of Europe’s most urgent health challenges, affecting more than 85 million people. Through iCARE4CVD, a €22 million public–private collaboration led by Maastricht University and Novo Nordisk,…
How CimCure is developing vaccines designed to target the blood vessels that help tumours grow. In this video, Prof. Arjan Griffioen, Founder and CSO of CimCure and Professor of Experimental…
Vector Bioscience’s €2.5 million GENERA project was awarded through the EIC Transition Challenge call for novel RNA delivery methods and therapies. Running from August 2023 to August 2026, the project…
NanoCell Therapeutics (NanoCell) is a biotechnology company founded in 2021 with operations in Pennsylvania (USA) and Utrecht (NL), that has rapidly established itself as an innovator in non-viral DNA-based in-vivo…
In the final EIC Accelerator round of 2024, we supported TetraKit Technologies (Copenhagen, Denmark) towards their successful submission. We visited them at BioInnovation Institute (Copenhagen, Denmark) to celebrate the grant…
Teitur Trophics (Denmark) develops novel therapeutics for treating or preventing neurodegenerative diseases. In the final Eurostars round of 2024, their project ‘RE-HEAR’ was awarded ~€1 million from Eurostars to advance…
Amarna Therapeutics (NL) and Phenocell’s (FR) new Eurostars project deals with the development of the first cure for dry age-related macular degeneration (dAMD) using a breakthrough gene therapy platform. In…
In 2021, Catalyze and Sanquin Health Solutions, the parent company of Sanquin’s private activities, commenced a strategic partnership that continues today. To learn more about the impact of the partnership…
Mercurna’s new Eurostars project, NANOMED-KT, aims to develop a first-of-its-kind treatment for post transplantation-associated inflammation that contributes to delayed graft function (DGF). The project, which commenced in October 2024 and…